Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Alucinógenos y drogas disociativas [[electronic resource] ] : incluyendo la LSD, el PCP, la Ketamina, y el Dextrometorfano
| Alucinógenos y drogas disociativas [[electronic resource] ] : incluyendo la LSD, el PCP, la Ketamina, y el Dextrometorfano |
| Pubbl/distr/stampa | [Rockville, Md.] : , : National Institute on Drug Abuse, National Institutes of Health, , [2003] |
| Descrizione fisica | 1 electronic text : HTML file |
| Collana |
Instituto Nacional sobre el Abuso de Drogas serie de reportes de investigación
NIH publicación |
| Soggetto topico |
Hallucinogenic drugs
Psychotropic drugs Hallucinogenic plants |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Altri titoli varianti | Alucinógenos y drogas disociativas |
| Record Nr. | UNINA-9910695715003321 |
| [Rockville, Md.] : , : National Institute on Drug Abuse, National Institutes of Health, , [2003] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antidepressant use among adults : United States, 2015-2018 / / Debra J. Brody, and Qiuping Gu
| Antidepressant use among adults : United States, 2015-2018 / / Debra J. Brody, and Qiuping Gu |
| Autore | Brody Debra J. |
| Pubbl/distr/stampa | Hyattsville, MD : , : U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, , 2020 |
| Descrizione fisica | 1 online resource (7 pages, 1 unnumbered page) : color illustrations |
| Collana | NCHS data brief |
| Soggetto topico |
Depression, Mental - Treatment
Antidepressants - United States Antidepressants Psychotropic drugs |
| Soggetto genere / forma | Statistics. |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Antidepressant use among adults |
| Record Nr. | UNINA-9910715343803321 |
Brody Debra J.
|
||
| Hyattsville, MD : , : U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard
| The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard |
| Autore | Brown Robert <1949-> |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Exeter [England], : Learning Matters, 2009 |
| Descrizione fisica | 1 online resource (145 p.) |
| Disciplina |
362.2
616.8918 |
| Altri autori (Persone) |
AdsheadGwen
PollardAlan |
| Collana | Post-qualifying social work practice |
| Soggetto topico |
Psychiatric social work - Great Britain
Mental illness - Treatment Psychotropic drugs |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-84445-553-X
1-282-48464-8 9786612484643 1-84445-830-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Prelims; Chapter 1 The importance of psychiatry and medication for Approved Mental Health Professionals; Chapter 2 Psychiatrists: training and how they practise; Chapter 3 An overview of psychiatry and classification; Chapter 4 Psychotic disorders; Chapter 5 Neurotic disorders, substance abuse and personality disorders; Chapter 6 Forensic psychiatry; Chapter 7 Psychiatry of old age; Chapter 8 Psychiatry and risk assessment; Chapter 9 Patients as parents; Chapter 10 Child and adolescent psychiatry; Chapter 11 Treatment issues in psychiatry
Chapter 12 Classification of medication in psychiatryChapter 13 Anti-depressants and mood stabilisers; Chapter 14 Anti-psychotics (BNF section 4.2); Chapter 15 Anxiolytics and sedative/ hypnotics (BNF section 4.1); Chapter 16 Older adults, children, unlicensed drugs; Chapter 17 The law and psychiatric treatment; Chapter 18 Treatment under the Mental Health Act; Statutes; Some useful websites; References; Index |
| Record Nr. | UNINA-9910456487803321 |
|
Brown Robert <1949->
|
||
| Exeter [England], : Learning Matters, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard
| The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard |
| Autore | Brown Robert <1949-> |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Exeter [England], : Learning Matters, 2009 |
| Descrizione fisica | 1 online resource (145 p.) |
| Disciplina |
362.2
616.8918 |
| Altri autori (Persone) |
AdsheadGwen
PollardAlan |
| Collana | Post-qualifying social work practice |
| Soggetto topico |
Psychiatric social work - Great Britain
Mental illness - Treatment Psychotropic drugs |
| ISBN |
1-84445-553-X
1-282-48464-8 9786612484643 1-84445-830-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Prelims; Chapter 1 The importance of psychiatry and medication for Approved Mental Health Professionals; Chapter 2 Psychiatrists: training and how they practise; Chapter 3 An overview of psychiatry and classification; Chapter 4 Psychotic disorders; Chapter 5 Neurotic disorders, substance abuse and personality disorders; Chapter 6 Forensic psychiatry; Chapter 7 Psychiatry of old age; Chapter 8 Psychiatry and risk assessment; Chapter 9 Patients as parents; Chapter 10 Child and adolescent psychiatry; Chapter 11 Treatment issues in psychiatry
Chapter 12 Classification of medication in psychiatryChapter 13 Anti-depressants and mood stabilisers; Chapter 14 Anti-psychotics (BNF section 4.2); Chapter 15 Anxiolytics and sedative/ hypnotics (BNF section 4.1); Chapter 16 Older adults, children, unlicensed drugs; Chapter 17 The law and psychiatric treatment; Chapter 18 Treatment under the Mental Health Act; Statutes; Some useful websites; References; Index |
| Record Nr. | UNINA-9910780819003321 |
|
Brown Robert <1949->
|
||
| Exeter [England], : Learning Matters, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard
| The approved mental health professional's guide to psychiatry and medication [[electronic resource] /] / Robert Brown, Gwen Adshead, Alan Pollard |
| Autore | Brown Robert <1949-> |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Exeter [England], : Learning Matters, 2009 |
| Descrizione fisica | 1 online resource (145 p.) |
| Disciplina |
362.2
616.8918 |
| Altri autori (Persone) |
AdsheadGwen
PollardAlan |
| Collana | Post-qualifying social work practice |
| Soggetto topico |
Psychiatric social work - Great Britain
Mental illness - Treatment Psychotropic drugs |
| ISBN |
1-84445-553-X
1-282-48464-8 9786612484643 1-84445-830-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Prelims; Chapter 1 The importance of psychiatry and medication for Approved Mental Health Professionals; Chapter 2 Psychiatrists: training and how they practise; Chapter 3 An overview of psychiatry and classification; Chapter 4 Psychotic disorders; Chapter 5 Neurotic disorders, substance abuse and personality disorders; Chapter 6 Forensic psychiatry; Chapter 7 Psychiatry of old age; Chapter 8 Psychiatry and risk assessment; Chapter 9 Patients as parents; Chapter 10 Child and adolescent psychiatry; Chapter 11 Treatment issues in psychiatry
Chapter 12 Classification of medication in psychiatryChapter 13 Anti-depressants and mood stabilisers; Chapter 14 Anti-psychotics (BNF section 4.2); Chapter 15 Anxiolytics and sedative/ hypnotics (BNF section 4.1); Chapter 16 Older adults, children, unlicensed drugs; Chapter 17 The law and psychiatric treatment; Chapter 18 Treatment under the Mental Health Act; Statutes; Some useful websites; References; Index |
| Record Nr. | UNINA-9910814162703321 |
|
Brown Robert <1949->
|
||
| Exeter [England], : Learning Matters, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Aspects of psychopharmacology / / edited by D.J. Sanger and D.E. Blackman
| Aspects of psychopharmacology / / edited by D.J. Sanger and D.E. Blackman |
| Pubbl/distr/stampa | Abingdon, Oxon : , : Routledge, , 2017 |
| Descrizione fisica | 1 online resource (240 pages) : illustrations, graphs |
| Disciplina | 615.78 |
| Altri autori (Persone) |
Blackmanderek E
SangerD. J |
| Collana | Routledge Library Editions: Addictions |
| Soggetto topico |
Psychopharmacology
Psychotropic drugs Substance abuse |
| ISBN |
1-315-53605-6
1-315-53604-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Introduction to psychopharmacology and basic neuropharmacology / A.J. Greenshaw, D.J. Sanger and D.E. Blackman -- 2. Behavioural principles in psychopharmacology / James E. Barrett -- 3. Internal stimulus effects of drugs / I.P. Stolerman -- 4. Alcohol and alcoholism / Geoff Lowe -- 5. Social aspects of illegal drug use / Raymond Cochrane -- 6. Drugs and human memory / C.M. Smith -- 7. The use of drugs in psychiatry / P.E. Harrison-Read -- 8. Contemporary psychopharmacology : a review / D.J. Sanger and D.E. Blackman. |
| Record Nr. | UNINA-9910136150103321 |
| Abingdon, Oxon : , : Routledge, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical manual of psychopharmacology in the medically ill / / edited by James L. Levenson, M.D., Stephen J. Ferrando, M.D
| Clinical manual of psychopharmacology in the medically ill / / edited by James L. Levenson, M.D., Stephen J. Ferrando, M.D |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | Arlington, Virginia : , : American Psychiatric Association Publishing, , [2017] |
| Descrizione fisica | 1 online resource (xxv, 838 pages) : illustrations |
| Disciplina | 615.78 |
| Soggetto topico | Psychotropic drugs |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-61537-107-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910494650103321 |
| Arlington, Virginia : , : American Psychiatric Association Publishing, , [2017] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler
| Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010 |
| Descrizione fisica | 1 online resource (422 p.) |
| Disciplina | 615/.78 |
| Altri autori (Persone) |
HertzmanMarc
AdlerLawrence |
| Soggetto topico |
Psychopharmacology
Psychotropic drugs Clinical trials |
| ISBN |
1-282-54816-6
9786612548161 0-470-74918-0 0-470-74917-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials in Psychopharmacology; Contents; Acknowledgments; Introduction; List of Contributors; SECTION I: The Health Care Environment and Medications; 1. FDA Reform: D ́ej`a vu Encore; 1.1 Introduction; 1.2 The 1992 prescription drug user fee act adds funds and changes FDA's focus; 1.3 PDUFA shortens drug review times and eliminates the drug lag; 1.4 PDUFA timetables feed safety concerns; 1.5 FDA responds to safety concerns; 1.6 The pipeline problem; 1.7 The 2007 FDA Science Board's Subcommittee on Science and Technology report
1.8 The FDAAA of 2007 reauthorize PDUFA and provide new authority to address safety and the critical path initiative1.9 The impact of PDFUA on FDA; 1.10 Comparative medical benefits, comparative effectiveness and FDA; 1.11 FDA and non-inferiority trials; 1.12 FDA and CMS decisions on Medicare coverage; 1.13 Preemption: FDA's role in relation to liability litigation in state courts; 1.14 FDA's exclusivity in allowing access to experimental drugs; 1.15 Conclusions; 2. Do Antidepressants Cause Suicide?; 2.1 Some definitional problems 2.2 A brief history of the concerns of suicidality caused by antidepressants2.3 Politics rears its ugly head; 2.4 The FDA responds; 2.5 What changes in public policy wrought; 2.6 A funny thing happened on the way to the forum; 2.7 Meanwhile back at the ranch; 2.8 Moral (maybe); 3. The Genome, Genes and Brain - Tailored Drugs; 3.1 Introduction; 3.2 Issues in new drug development; 3.3 Early development of psychiatric pharmaceutical entities; 3.4 Advances in research technology; 3.5 Review of genetics; 3.6 Activation of genes by signal transduction cascades; 3.7 The human genome 3.8 The sequencing of the genome3.9 DNA variation; 3.10 Genes and illness; 3.11 Genomic findings, potential targets and new drug development; 3.12 Conclusion; 4. Patenting and Licensing Concerns in Psychiatric Genetics; 4.1 Genetic diagnoses in psychiatry; 4.2 The evolving patent landscape in psychiatry; 4.3 Approaches to solving potential problems; 4.4 Conclusions; 5. Women's Issues in Clinical Trials; 5.1 History; 5.2 Perceived advantages of excluding women; 5.3 Change in perspective; 5.4 Have things changed?; 5.5 Progress since 1993; 5.6 Reported current difficulties in including women 5.7 Contraception in clinical trials5.8 Drugs in lactating women; 5.9 How often do women take drugs during pregnancy?; 5.10 Ethical issues: risk/benefit analysis; 5.11 Adequate information; 5.12 Adolescent women; 5.13 Recruitment and retention of women; SECTION II: Clinical Trials and Mood Disorders; 6. Issues and Clues in the Pharmacological Treatment of Mood Disorders; 6.1 What do we know about mood disorders that may be relevant for their pharmacological treatment?; 6.2 Are there clues for the pharmacological treatment of mood disorders?; 6.3 Perspectives; 7. Bipolar Disorder 7.1 Introduction |
| Record Nr. | UNINA-9910139427703321 |
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler
| Clinical trials in psychopharmacology [[electronic resource] ] : a better brain / / editors, Marc Hertzman, Lawrence Adler |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010 |
| Descrizione fisica | 1 online resource (422 p.) |
| Disciplina | 615/.78 |
| Altri autori (Persone) |
HertzmanMarc
AdlerLawrence |
| Soggetto topico |
Psychopharmacology
Psychotropic drugs Clinical trials |
| ISBN |
1-282-54816-6
9786612548161 0-470-74918-0 0-470-74917-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Clinical Trials in Psychopharmacology; Contents; Acknowledgments; Introduction; List of Contributors; SECTION I: The Health Care Environment and Medications; 1. FDA Reform: D ́ej`a vu Encore; 1.1 Introduction; 1.2 The 1992 prescription drug user fee act adds funds and changes FDA's focus; 1.3 PDUFA shortens drug review times and eliminates the drug lag; 1.4 PDUFA timetables feed safety concerns; 1.5 FDA responds to safety concerns; 1.6 The pipeline problem; 1.7 The 2007 FDA Science Board's Subcommittee on Science and Technology report
1.8 The FDAAA of 2007 reauthorize PDUFA and provide new authority to address safety and the critical path initiative1.9 The impact of PDFUA on FDA; 1.10 Comparative medical benefits, comparative effectiveness and FDA; 1.11 FDA and non-inferiority trials; 1.12 FDA and CMS decisions on Medicare coverage; 1.13 Preemption: FDA's role in relation to liability litigation in state courts; 1.14 FDA's exclusivity in allowing access to experimental drugs; 1.15 Conclusions; 2. Do Antidepressants Cause Suicide?; 2.1 Some definitional problems 2.2 A brief history of the concerns of suicidality caused by antidepressants2.3 Politics rears its ugly head; 2.4 The FDA responds; 2.5 What changes in public policy wrought; 2.6 A funny thing happened on the way to the forum; 2.7 Meanwhile back at the ranch; 2.8 Moral (maybe); 3. The Genome, Genes and Brain - Tailored Drugs; 3.1 Introduction; 3.2 Issues in new drug development; 3.3 Early development of psychiatric pharmaceutical entities; 3.4 Advances in research technology; 3.5 Review of genetics; 3.6 Activation of genes by signal transduction cascades; 3.7 The human genome 3.8 The sequencing of the genome3.9 DNA variation; 3.10 Genes and illness; 3.11 Genomic findings, potential targets and new drug development; 3.12 Conclusion; 4. Patenting and Licensing Concerns in Psychiatric Genetics; 4.1 Genetic diagnoses in psychiatry; 4.2 The evolving patent landscape in psychiatry; 4.3 Approaches to solving potential problems; 4.4 Conclusions; 5. Women's Issues in Clinical Trials; 5.1 History; 5.2 Perceived advantages of excluding women; 5.3 Change in perspective; 5.4 Have things changed?; 5.5 Progress since 1993; 5.6 Reported current difficulties in including women 5.7 Contraception in clinical trials5.8 Drugs in lactating women; 5.9 How often do women take drugs during pregnancy?; 5.10 Ethical issues: risk/benefit analysis; 5.11 Adequate information; 5.12 Adolescent women; 5.13 Recruitment and retention of women; SECTION II: Clinical Trials and Mood Disorders; 6. Issues and Clues in the Pharmacological Treatment of Mood Disorders; 6.1 What do we know about mood disorders that may be relevant for their pharmacological treatment?; 6.2 Are there clues for the pharmacological treatment of mood disorders?; 6.3 Perspectives; 7. Bipolar Disorder 7.1 Introduction |
| Record Nr. | UNINA-9910813016803321 |
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Comite de Expertos de los OMS en Farmacodependencia [[electronic resource] ] : 33o informe / / Organizacion Mundial de la Salud
| Comite de Expertos de los OMS en Farmacodependencia [[electronic resource] ] : 33o informe / / Organizacion Mundial de la Salud |
| Pubbl/distr/stampa | Ginebra, : Organizacion Mundial de la Salud, 2003 |
| Descrizione fisica | 1 online resource (33 p.) |
| Collana | OMS, serie de informes tecnicos |
| Soggetto topico |
Psychotropic drugs
Drugs |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-08456-1
9781417531096 9786610084562 1-4175-3109-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Record Nr. | UNINA-9910450281603321 |
| Ginebra, : Organizacion Mundial de la Salud, 2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Psychotropic drugs
(106)
- Psychopharmacology (40)
- Psychotropic Drugs (16)
- Psychotropes (8)
- Mental illness - Treatment (7)